Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...

JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic ...

When you think of arthritis, achy, warm, swollen joints probably come to mind. These are indeed some of the most common symptoms of arthritis. But did you know there are actually over 100 different ...

SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...

PHILADELPHIA — Patients with gout who underwent an intensive treat-to-target regimen of monthly up-titration of urate-lowering therapy (ULT) to reach a target serum urate level were significantly more ...

US-based biotechnology company Arthrosi Therapeutics has completed a series E funding round, amassing $153m which is earmarked to advance the clinical development of its flagship programme, ...

Xanthine oxidase inhibitors, primarily allopurinol and febuxostat, are the mainstay of treatment. The goal of chronic gout management includes lowering serum urate levels to below 6 mg/dL. 5 Overall, ...

Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels. Bone erosion in patients with gout and tophi was associated ...

Male doctor with senior male patient. Suneet Grewal, MD, provides a deeper insight into the impact of uncontrolled gout on the quality of life of patients and the importance of having an open dialogue ...

Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. An ...